论文部分内容阅读
目的观察纳络酮联合重组组织型纤溶酶原激活剂(rt-PA)治疗急性脑梗死的临床疗效,并评定其安全性。方法将我院2012年1月-2013年2月间收治的118例急性脑梗死患者随机分为两组各59例,rt-PA组给予rt-PA治疗,联合组在rt-PA组基础上加用纳络酮,比较两组ESS评分、总有效率等。结果联合组治疗后ESS评分和总有效率均显著高于rt-PA组,组间差异显著(P<0.01);两组不良反应发生率均较低。结论纳络酮联合rt-PA治疗急性脑梗死疗效显著,安全可靠,值得临床推广应用。
Objective To observe the clinical efficacy of naloxone combined with recombinant tissue plasminogen activator (rt-PA) in the treatment of acute cerebral infarction and evaluate its safety. Methods A total of 118 patients with acute cerebral infarction who were admitted to our hospital from January 2012 to February 2013 were randomly divided into two groups of 59 cases. Rt-PA group was treated with rt-PA. On the basis of rt-PA group Add naloxone, ESS scores were compared between the two groups, the total effective rate. Results The ESS score and total effective rate in the combined group were significantly higher than those in rt-PA group (P <0.01). The incidence of adverse reactions in both groups was low. Conclusion Naloxone combined with rt-PA in the treatment of acute cerebral infarction has obvious curative effect, which is safe and reliable, which is worthy of clinical application.